Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 2943-2952

  Cocconi, G ^a   Cunningham, D ^b   Van Cutsem, E ^b   Francois, E ^b   Gustavsson, B ^b   Van Hazel, G ^b   Kerr, D ^b   Possinger, K ^b   Hietschold, S M ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; RALTITREXED;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT OUTCOME;

EID: 0031671255     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.2943     Document Type: Article

References (34)

1. Lynn AG, Ries MS: Top five cancers for females and males in the US. J Natl Cancer Inst 87:867, 1995
2. Esteve J, Kricker A, Ferlay J, et al (eds): Facts and Figures of Cancer in the European Community. IARC, Lyon, France, 1993
3. Schmoll H-J: Colorectal carcinoma: Current problems and future perspectives. Ann Oncol 5:S115-S121, 1994
4. Sinicrope FA, Sugarman SM: Role of adjuvant therapy in surgically resected colorectal carcinoma. Gastroenterology 109:984-993, 1995
5. Scheithauer W, Rosen H, Kornek GV, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306:752-755, 1993
6. Nordic Gastrointestinal Tumour Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer. A randomized trial. J Clin Oncol 10:904-911, 1992
7. Beretta G, Bollina R, Martignoni M, et al: Fluorouracil + folates (FUFO) as standard treatment for advanced/metastatic gastrointestinal carcinomas (AGC). Ann Oncol 5:1994 (abstr 239)
8. Glimelius B, Hoffman K, Graf W, et al: Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 6:267-274, 1995
9. Labianca R, Pancera G, Luporini G: Factors influencing response rates for advanced colorectal cancer. Ann Oncol 7:901-906, 1996
10. Jackman AL, Judson IR: The new generation of thymidylate synthase inhibitors in clinical study. Exp Opin Invest Drugs 5:719-736, 1996
11. Rustum YM, Harstrick A, Shousong C, et al: Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors. J Clin Oncol 15:389-400, 1997
12. Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4:685-696, 1986
13. Di Costanzo F, Bartolucci R, Calabresi F, et al: Fluorouracil alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 3:371-376, 1992
14. Valone FH, Friedman MA, Wittlinger PS, et al: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-1436, 1989
15. Labianca R, Pancera G, Aitini E, et al: Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 2:673-679, 1991
16. Cunningham D, Zalcberg JR, Rath U, et al: Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 7:961-965, 1996
17. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. Geneva, Switzerland, WHO, 1979
18. Hayward JL, Carbone PP, Henson JC, et al: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13:89-94, 1977
19. De Haes JCJM: Measuring the Quality of Life of Cancer Patients with the Rotterdam Symptom Checklist - A manual. Groningen, The Netherlands, Northern Centre for Healthcare Research, University of Groningen, 1996
20. Kind P, Gudex C, Dolan P, et al: Practical and methodological issues in the development of the EuroQoL: The York experience. Adv Med Sociol 5:219-253, 1994
21. Holm S: A simple sequentially rejective multiple test procedure. Scand J Stat 6:65-70, 1979
22. Ratain MJ, Cooper N, Smith R, et al: Phase I study of ZD9331: A novel thymidylate synthase (TS) inhibitor. Proc Am Soc Clin Oncol 16:208a, 1997 (abstr 729)
23. Pazdur R, Vincent M: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU+LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicentre, North American trial. Proc Am Soc Clin Oncol 16:1997 (abstr 801)
24. Clarke SJ, Hanwell J, De Boer, et al: Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 14:1495-1503, 1996
25. Zalcberg JR, Cunningham D, Van Cutsem E, et al: ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 14:716-721, 1996
26. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989
27. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994
28. Poon MA, O'Connell MJ, Weiand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
29. Corfu - A Study Group: Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13:921-928, 1995
30. Scheithauer W, Depisch D, Kornek G, et al: Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin and cisplatin therapy in patients with advanced colorectal cancer. Cancer 73:1562-1568, 1994
31. Labianca R, Cascinu S, Frontini L, et al: High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A 'GISCAD' phase III study. Ann Oncol 8:169-174, 1997
32. Topham C: A survey of patients' perceptions of the convenience of different chemotherapy regimens for advanced colorectal cancer. Eur J Cancer Care 6:208-211, 1997
33. Summerhayes M, Wanklyn SJ, Shakespeare RA, et al: Reduced pharmacy resource utilisation associated with raltitrexed treatment of advanced colorectal cancer. J Oncol Pharm Prac 3:13-19, 1997
34. Ross P, Heron J, Cunningham D: Cost of treating advanced colorectal cancer: A retrospective comparison of treatment regimens. Eur J Cancer 32A:S13-S17, 1996 (suppl 5)